Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Melanoma

  Free Subscription


03.02.2025

1 Am J Surg
1 Ann Surg Oncol
1 Arch Pathol Lab Med
1 Biochem Biophys Res Commun
1 Clin Exp Metastasis
2 Curr Opin Oncol
2 Melanoma Res
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Surg

  1. WILSON NR, Angeles CV, Haykal T
    Neoadjuvant treatment in advanced resectable melanoma and the need for a predictive biomarker - is pathologic complete response (pCR) the answer?
    Am J Surg. 2025 Jan 21:116207. doi: 10.1016/j.amjsurg.2025.116207.
    PubMed        


    Ann Surg Oncol

  2. PAZHAVA A, Yu WY, Jing FZ, Hill S, et al
    Correction: Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP).
    Ann Surg Oncol. 2025 Jan 30. doi: 10.1245/s10434-025-16946.
    PubMed        


    Arch Pathol Lab Med

  3. SRIRAM S, Kakkar A, Sarma C, Mahendru R, et al
    Frequent Immunohistochemical Expression of Transcriptional Repressor GATA Binding 1 in Salivary Gland Neoplasms: A Sensitive but Nonspecific Marker.
    Arch Pathol Lab Med. 2025;149:165-174.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  4. ALAMODI ALGHAMDI M, Deshpande H
    Selective inhibition of p300 by a novel small molecule EPS496 promotes cell death in vemurafenib-resistant BRAF(V600E) mutated melanoma cells.
    Biochem Biophys Res Commun. 2025;750:151382.
    PubMed         Abstract available


    Clin Exp Metastasis

  5. WIKERHOLMEN T, Taule EM, Rigg E, Berle BF, et al
    Repurposing neuroleptics: clozapine as a novel, adjuvant therapy for melanoma brain metastases.
    Clin Exp Metastasis. 2025;42:12.
    PubMed         Abstract available


    Curr Opin Oncol

  6. MOUNA O, Hanssens C, Meyers M, Langouo M, et al
    Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy.
    Curr Opin Oncol. 2025 Jan 16. doi: 10.1097/CCO.0000000000001118.
    PubMed         Abstract available

  7. MEYERS M, Mouna O, Langouo M
    Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?
    Curr Opin Oncol. 2024 Dec 30. doi: 10.1097/CCO.0000000000001119.
    PubMed         Abstract available


    Melanoma Res

  8. ANGELL CD, Sun SH, Lapurga G, Benner B, et al
    A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.
    Melanoma Res. 2025 Jan 29. doi: 10.1097/CMR.0000000000001023.
    PubMed         Abstract available

  9. CHEN L, Cai B, Ni X, Lin Q, et al
    Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety.
    Melanoma Res. 2025 Jan 28. doi: 10.1097/CMR.0000000000001021.
    PubMed         Abstract available


    PLoS One

  10. HUGDAHL E, Aziz S, Klingen TA, Akslen LA, et al
    Prognostic value of immune biomarkers in melanoma loco-regional metastases.
    PLoS One. 2025;20:e0315284.
    PubMed         Abstract available

  11. SHIRALKAR J, Anthony T, McCallum GA, Durand DM, et al
    Correction: Neural recordings can differentiate between spontaneously metastasizing melanomas and melanomas with low metastatic potential.
    PLoS One. 2025;20:e0318831.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.